Lantern Pharma Inc (LTRN) Stock Analysis
Verdict: AVOID
Rapid cash burn (~6 months runway) and ongoing dilution risk outweigh AI platform potential, driving a severe technical downtrend.
Investment score: 27/100
Analysis as of
Is Lantern Pharma Inc stock worth reviewing? AI model thesis
The AI model views LTRN as an AVOID due to zero revenue, severe quarterly cash burn (~$3.52M/quarter), under 7 months of remaining runway, and ongoing dilution risk.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Lantern Pharma Inc opportunities and risks
What speaks for LTRN
- Proprietary RADR AI platform commercialization and OMAI subsidiary spin-out
What speaks against LTRN
- Short cash runway (~6.3 months) creates imminent dilution risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LTRN | n/a | 0.0x | n/a | 0.0% | 0.0% | -91.2% |
| BCDA | n/a | 0.0x | n/a | 0.0% | 0.0% | -47.5% |
| SHPH | n/a | 0.0x | n/a | 0.0% | 0.0% | -279.8% |
| PASG | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -217.2% |
| ACTU | n/a | 0.0x | n/a | 0.0% | 0.0% | -133.7% |
| CNSY | n/a | 3.1x | n/a | 89.6% | -620.7% | -183.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -183.0% |
Frequently asked questions about Lantern Pharma Inc (LTRN)
Is LTRN stock a good investment?
The cached TradeMates AI model rates Lantern Pharma Inc as AVOID with an investment score of 27/100. The AI model views LTRN as an AVOID due to zero revenue, severe quarterly cash burn (~$3.52M/quarter), under 7 months of remaining runway, and ongoing dilution risk. This is algorithmic model output, not personal investment advice.
Is LTRN stock a buy?
The TradeMates model verdict for LTRN is AVOID with an investment score of 27/100. Treat this as a model signal to review, not a personal buy recommendation.